Conferon

Base Information

• Chemical Name: Conferon
• CAS No.: 9004-66-4
• Molecular Formula: FeH2O4S
• Molecular Weight: 1347.3642
• European Community (EC) Number: 233-336-3,618-390-1,933-787-2
• NSC Number: 146177,57631
• DSSTox Substance ID: DTXSID80906016
• NCI Thesaurus Code: C76837
• Mol file: 9004-66-4.mol

Synonyms:Dexferrum;Dextran Iron Complex;Dextran-Iron Complex;Dextrofer;Feosol;Ferridextran;Hematran;Icar;Imfergen;Imferon;Imperon;Imposil;InFed;Iron Dextran Complex;Iron-Dextran Complex;Norferan

Chemical Property of Conferon

Chemical Property:

• Appearance/Colour: Dark reddish-brown liquid
• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: Room Temperature
• Solubility.: Water (Slightly)
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 0
• Exact Mass: 153.902315
• Heavy Atom Count: 6
• Complexity: 81.3

Purity/Quality:

99%, ^*data from raw suppliers

Iron dextran ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn,T
• Statements: 40-42/43-43-45
• Safety Statements: 23-26-36/37/39-45-36-36/37-53

MSDS Files:

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: OS(=O)(=O)O.[Fe]
• Recent ClinicalTrials: Practical Anemia Bundle for SusTained Blood Recovery
• Recent EU Clinical Trials: Predicting Response to Iron Supplementation in Patients with Inflammatory Bowel Disease during Induction Therapy
• Description: Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292) Iron-Dextran is for the parenteral treatment of iron-deficiency anemia in humans and baby pigs. Can be used as a reagent.
• Uses: Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.
• Clinical Use: Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated) Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL)
• Drug interactions: Potentially hazardous interactions with other drugs Dimercaprol: avoid concomitant use. Oral iron: reduced absorption of oral iron